Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (8.1), the stock would be worth R$21.38 (32% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.9 | R$31.5 |
0%
|
| 3-Year Average | 8.1 | R$21.38 |
-32%
|
| 5-Year Average | 9.2 | R$24.5 |
-22%
|
| Country Average | 10.6 | R$28.2 |
-10%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| BR |
|
Ouro Fino Saude Animal Participacoes SA
BOVESPA:OFSA3
|
1.7B BRL | 11.9 | 7.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 61.3 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 37.8 | 4 516.9 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 7.9 |
| Median | 10.6 |
| 70th Percentile | 17.3 |
| Max | 51 841.7 |
Other Multiples
Ouro Fino Saude Animal Participacoes SA
Glance View
Ouro Fino Saúde Animal Participações SA engages in the development, production, and sale of veterinary drugs, vaccines, and other products for production and companion animals. The firm manufactures veterinary products using scientific technology in the Company's laboratories. The firm's products are divided into six sectors: Wholesale, Birds, Cattle, Equine, Pet and Pigs. The Wholesale area is divided into four lines: Anti-Mastiticos, producing antibiotics killing bacteria and lumps; Antimicrobial, which focuses on the treatment of bacterial infectious diseases; Ectoparasiticides, concentrated on insect repellent products, and Endectocides, which is the treatment and control of internal and external diseases of cattle, sheep and swine parasites. There is also one additional line of products divided for additives, biological, inoculants, diagnostic kit, probiotics, silage and other supplements, among others.
